Metastatic Urothelial Carcinoma (UC) (DBCOND0073677)

Identifiers

Synonyms

Metastatic urothelial cell carcinoma / Metastatic Urothelial Carcinoma / Metastatic urothelial carcinoma (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Atezolizumab	A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.	Programmed cell death 1 ligand 1target Programmed cell death protein 1target
Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.	Programmed cell death protein 1target Programmed cell death 1 ligand 1target
Pemetrexed	A folate analog used to treat mesothelioma and non-small cell lung cancer.	Thymidylate synthasetarget Dihydrofolate reductasetarget Trifunctional purine biosynthetic protein adenosine-3target Deoxycytidine kinaseenzyme Bifunctional purine biosynthesis protein ATICtarget Equilibrative nucleoside transporter 1enzyme Organic anion transporter 3transporter Reduced folate transportertransporter Proton-coupled folate transportertransporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-binding cassette sub-family C member 5transporter Solute carrier family 22 member 6transporter Albumincarrier Solute carrier family 22 member 11transporter Thymidylate synthasetarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02334527	Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy	Palbociclib	treatment	2	terminated
NCT04579224	Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer	Docetaxel Eribulin Gemcitabine Paclitaxel Sacituzumab govitecan	treatment	3	recruiting
NCT04963153	Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy	Enfortumab vedotin Erdafitinib	treatment	1	recruiting
NCT06483334	A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)	Enfortumab vedotin Pembrolizumab Sacituzumab tirumotecan	treatment	1 / 2	recruiting
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Cabozantinib Nivolumab	treatment	1	active_not_recruiting
NCT05544552	Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations	No drug interventions	treatment	1 / 2	recruiting
NCT04953104	Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	Nivolumab Relatlimab	treatment	2	recruiting
NCT06493552	Modular Trial of SEphB4-HSA in EphrinB2-High Solid Tumors	Cisplatin Enfortumab vedotin Gemcitabine Pembrolizumab SEphB4-HSA	treatment	2 / 3	not_yet_recruiting
NCT03071328	INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers	Iopamidol	other	0	completed
NCT03744793	Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer	Avelumab Pemetrexed	treatment	2	active_not_recruiting
NCT06439836	Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy	Emavusertib Pembrolizumab	treatment	1	not_yet_recruiting
NCT03047213	Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	Sapanisertib	treatment	2	active_not_recruiting
NCT04724018	Sacituzumab Govitecan Plus EV in Metastatic UC	Enfortumab vedotin Sacituzumab govitecan	treatment	1	active_not_recruiting
NCT04848519	Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma	Avelumab Nivolumab Pembrolizumab Propranolol	treatment	2	recruiting
NCT02693717	Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer	Pemetrexed	treatment	2	terminated
NCT03464734	Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma	Albumin human Paclitaxel Pembrolizumab	treatment	2	completed
NCT02351739	Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer	Acalabrutinib Pembrolizumab	treatment	2	completed
NCT00365157	Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction	Eribulin	treatment	1 / 2	active_not_recruiting
NCT05107674	A Study of NX-1607 in Adults With Advanced Malignancies	Paclitaxel	treatment	1	recruiting
NCT04637594	Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy	Atezolizumab Avelumab Durvalumab Nivolumab Pembrolizumab	treatment	3	active_not_recruiting
NCT03397394	Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma	Rucaparib	treatment	2	terminated
NCT04878029	Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer	Cabozantinib Enfortumab vedotin	treatment	1	recruiting
NCT05940844	Study of OB-002 in Patients With Refractory Metastatic Cancer	No drug interventions	treatment	1	not_yet_recruiting
NCT04007744	Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Pembrolizumab Sonidegib	treatment	1	recruiting
NCT06524544	A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Sacituzumab Govitecan Alone in the Treatment of Advanced Urothelial Cancer	Pembrolizumab Sacituzumab govitecan	treatment	3	not_yet_recruiting
NCT04383067	A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients	Aldesleukin	treatment	2	unknown_status
NCT03115801	A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers	Atezolizumab Nivolumab Pembrolizumab	treatment	2	terminated
NCT03534804	Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma	Cabozantinib Pembrolizumab	treatment	2	active_not_recruiting
NCT05052372	Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib	Erdafitinib	Not Available	Not Available	terminated
NCT04839510	A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer	Trastuzumab vedotin	treatment	2	unknown_status
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Cyclophosphamide Pembrolizumab Sargramostim	treatment	1 / 2	recruiting
NCT05923190	Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma	Enfortumab vedotin Pembrolizumab	treatment	2	recruiting
NCT05895864	Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma	Utidelone	treatment	2	recruiting
NCT04623502	An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	No drug interventions	basic_science	Not Available	recruiting
NCT06129084	A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing	No drug interventions	Not Available	Not Available	recruiting
NCT03590054	Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies	Abexinostat Pembrolizumab	treatment	1	completed
NCT06050954	A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)	Pembrolizumab	treatment	2	withdrawn
NCT04693377	Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial	No drug interventions	supportive_care	Not Available	recruiting
NCT02420847	Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery	Doxorubicin Gemcitabine Ixazomib	treatment	1 / 2	active_not_recruiting
NCT04639245	Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	Atezolizumab Cyclophosphamide Fludarabine	treatment	1 / 2	terminated
NCT04863885	Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients	Ipilimumab Nivolumab Sacituzumab govitecan	treatment	1 / 2	active_not_recruiting
NCT06265285	Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	Nivolumab	health_services_research	2	recruiting
NCT04388852	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	Ipilimumab Valemetostat	treatment	1	recruiting
NCT03513952	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma	Atezolizumab Interleukin-7	treatment	2	completed
NCT05733000	CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Devimistat Fluorouracil Gemcitabine Hydroxychloroquine Lipoic acid	treatment	2	recruiting
NCT04641936	Urine Omics Predicting IO Therapy Responses in mUC Patients	No drug interventions	Not Available	Not Available	recruiting
NCT04701918	Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma	Avelumab Pembrolizumab	treatment	2	recruiting
NCT01552434	Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease	Bevacizumab Cetuximab Menthol Sirolimus Temsirolimus Valproic acid	treatment	1	active_not_recruiting
NCT06018116	A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.	Avelumab Bicalutamide	treatment	2	withdrawn
NCT04200963	A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma	Nivolumab	treatment	1	completed
NCT04936230	Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer	Pembrolizumab	treatment	2	active_not_recruiting
NCT03854474	Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma	Pembrolizumab Tazemetostat	treatment	1 / 2	active_not_recruiting
NCT00942331	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer	Bevacizumab Chloride ion Cisplatin Gemcitabine Platinum	treatment	3	completed
NCT05154994	Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma	Belinostat Durvalumab	treatment	1	suspended
NCT04856189	Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma	Escitalopram Pembrolizumab Selinexor	treatment	1 / 2	recruiting
NCT03682289	Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors	Adenosine Ceralasertib Durvalumab Olaparib Ribose	treatment	2	recruiting
NCT05700344	SOGUG-AVELUMAB_RWD	Avelumab	Not Available	Not Available	completed
NCT04003610	Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)	Carboplatin Gemcitabine Pembrolizumab Pemigatinib	treatment	2	terminated
NCT04486781	A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma	Pembrolizumab SEphB4-HSA	treatment	2	recruiting
NCT05845814	A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)	Enfortumab vedotin Favezelimab Pembrolizumab Vibostolimab	treatment	1 / 2	active_not_recruiting